No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 1djwB, 1.0000, 0.00, 1.000, 561, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-2-METHYLENE-12-CYCLIC- MONOPHOSPHONATE
2, 1djzB, 0.9983, 0.17, 1.000, 561, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-45-BISPHOSPHATE
3, 2isdB, 0.9883, 0.54, 1.000, 561, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT
4, 1djhA, 0.9828, 0.77, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH BARIUM
5, 1djwA, 0.9826, 0.71, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-2-METHYLENE-12-CYCLIC- MONOPHOSPHONATE
6, 1djzA, 0.9817, 0.71, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-45-BISPHOSPHATE
7, 1djyA, 0.9810, 0.73, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-245-TRISPHOSPHATE
8, 1djyB, 0.9805, 0.83, 1.000, 561, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-245-TRISPHOSPHATE
9, 1djiA, 0.9802, 0.88, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH CALCIUM
10, 1djxB, 0.9800, 0.92, 1.000, 561, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-145-TRISPHOSPHATE
11, 1djxA, 0.9799, 0.86, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH INOSITOL-145-TRISPHOSPHATE
12, 1djgA, 0.9798, 0.88, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH LANTHANUM
13, 2isdA, 0.9797, 0.91, 1.000, 513, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT
14, 1djgB, 0.9790, 0.88, 1.000, 561, 131, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH LANTHANUM
15, 1djhB, 0.9787, 0.38, 1.000, 559, 129, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH BARIUM
16, 1djiB, 0.9780, 0.40, 1.000, 559, 129, PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA1 FROM RAT COMPLEXED WITH CALCIUM
17, 1qatA, 0.9604, 1.12, 1.000, 509, 131, 1-PHOSPHATIDYLINOSITOL-45-BISPHOSPHATE PHOSPHODIESTERASE DELTA COMPLEX WITH SAMARIUM (III) CHLORIDE
18, 1qatB, 0.9602, 1.20, 1.000, 507, 131, 1-PHOSPHATIDYLINOSITOL-45-BISPHOSPHATE PHOSPHODIESTERASE DELTA COMPLEX WITH SAMARIUM (III) CHLORIDE
19, 1qasB, 0.9516, 0.49, 1.000, 504, 126, 1-PHOSPHATIDYLINOSITOL-45-BISPHOSPHATE PHOSPHODIESTERASE DELTA 1
20, 1qasA, 0.9487, 0.55, 0.992, 505, 126, 1-PHOSPHATIDYLINOSITOL-45-BISPHOSPHATE PHOSPHODIESTERASE DELTA 1
21, 3qr1A, 0.8609, 1.29, 0.322, 781, 121, CRYSTAL STRUCTURE OF L. PEALEI PLC21
22, 3qr1D, 0.8608, 1.29, 0.322, 775, 121, CRYSTAL STRUCTURE OF L. PEALEI PLC21
23, 3qr0A, 0.8597, 1.31, 0.347, 781, 121, CRYSTAL STRUCTURE OF S. OFFICINALIS PLC21
24, 4qj4B, 0.8565, 1.29, 0.298, 749, 121, STRUCTURE OF A FRAGMENT OF HUMAN PHOSPHOLIPASE C-BETA3 DELTA472-569 BOUND TO IP3 AND IN COMPLEX WITH GALPHAQ
25, 4qj3B, 0.8538, 1.33, 0.298, 756, 121, STRUCTURE OF A FRAGMENT OF HUMAN PHOSPHOLIPASE C-BETA3 DELTA472-559 IN COMPLEX WITH GALPHAQ
26, 2zkmX, 0.8520, 1.36, 0.331, 708, 121, CRYSTAL STRUCTURE OF PHOSPHOLIPASE C BETA 2
27, 4gnkD, 0.8514, 1.36, 0.298, 766, 121, CRYSTAL STRUCTURE OF GALPHAQ IN COMPLEX WITH FULL-LENGTH HUMAN PLCBETA3
28, 4gnkB, 0.8513, 1.36, 0.298, 769, 121, CRYSTAL STRUCTURE OF GALPHAQ IN COMPLEX WITH FULL-LENGTH HUMAN PLCBETA3
29, 3ohmB, 0.8510, 1.36, 0.298, 759, 121, CRYSTAL STRUCTURE OF ACTIVATED G ALPHA Q BOUND TO ITS EFFECTOR PHOSPHOLIPASE C BETA 3
30, 4qj5B, 0.8492, 1.38, 0.298, 747, 121, STRUCTURE OF A FRAGMENT OF HUMAN PHOSPHOLIPASE C-BETA3 DELTA472-581 BOUND TO IP3 AND IN COMPLEX WITH GALPHAQ
31, 2fjuB, 0.8298, 1.36, 0.339, 696, 118, ACTIVATED RAC1 BOUND TO ITS EFFECTOR PHOSPHOLIPASE C BETA 2
32, 3kwuA, 0.8233, 1.92, 0.242, 135, 120, MUNC13-1 C2B-DOMAIN CALCIUM BOUND
33, 2nsqA, 0.8094, 2.42, 0.279, 140, 122, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF THE HUMAN E3 UBIQUITIN-PROTEIN LIGASE NEDD4-LIKE PROTEIN
34, 3pycA, 0.8026, 2.37, 0.172, 132, 122, CRYSTAL STRUCTURE OF HUMAN SMURF1 C2 DOMAIN
35, 3jzyA, 0.7996, 1.65, 0.233, 124, 116, CRYSTAL STRUCTURE OF HUMAN INTERSECTIN 2 C2 DOMAIN
36, 5iz5B, 0.7995, 2.01, 0.175, 746, 120, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2
37, 2fk9A, 0.7956, 1.83, 0.216, 140, 116, HUMAN PROTEIN KINASE C ETA
38, 4npkA, 0.7952, 1.97, 0.212, 269, 118, EXTENDED-SYNAPTOTAGMIN 2 C2A- AND C2B-DOMAINS CALCIUM BOUND
39, 3kwtA, 0.7951, 1.52, 0.239, 116, 113, MUNC13-1 C2B-DOMAIN CALCIUM-FREE
40, 1gmiA, 0.7948, 2.03, 0.188, 135, 117, STRUCTURE OF THE C2 DOMAIN FROM NOVEL PROTEIN KINASE C EPSILON
41, 4ihbE, 0.7942, 1.86, 0.229, 126, 118, X-RAY STRUCTURE OF THE CANONICAL C2A DOMAIN FROM HUMAN DYSFERLIN
42, 2ep6A, 0.7939, 2.03, 0.215, 133, 121, SOLUTION STRUCTURE OF THE SECOND C2 DOMAIN FROM HUMAN MCTP2 PROTEIN
43, 1rlwA, 0.7939, 2.07, 0.160, 126, 119, CALCIUM-PHOSPHOLIPID BINDING DOMAIN FROM CYTOSOLIC PHOSPHOLIPASE A2
44, 3l4cB, 0.7904, 2.23, 0.107, 179, 122, STRUCTURAL BASIS OF MEMBRANE-TARGETING BY DOCK180
45, 3l4cA, 0.7903, 2.26, 0.106, 178, 123, STRUCTURAL BASIS OF MEMBRANE-TARGETING BY DOCK180
46, 4p42B, 0.7889, 2.17, 0.190, 431, 116, EXTENDED-SYNAPTOTAGMIN 2 SMP - C2A - C2B DOMAINS
47, 1cjyB, 0.7887, 2.22, 0.167, 614, 120, HUMAN CYTOSOLIC PHOSPHOLIPASE A2
48, 4npjA, 0.7882, 2.23, 0.210, 292, 119, EXTENDED-SYNAPTOTAGMIN 2 C2A- AND C2B-DOMAINS
49, 4npjB, 0.7876, 1.87, 0.216, 282, 116, EXTENDED-SYNAPTOTAGMIN 2 C2A- AND C2B-DOMAINS
50, 4iqhB, 0.7864, 2.15, 0.227, 127, 119, CRYSTAL STRUCTURE ANALYSIS OF DYSFERLIN C2A VARIANT 1 (C2AV1)
51, 1cjyA, 0.7863, 2.25, 0.158, 633, 120, HUMAN CYTOSOLIC PHOSPHOLIPASE A2
52, 5izrB, 0.7860, 1.83, 0.190, 675, 116, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2 IN COMPLEX WITH METHYL GAMMA- LINOLENYL FLUOROPHOSPHONATE INHIBITOR AND TERBIUM CHLORIDE
53, 5ixcA, 0.7845, 1.80, 0.183, 684, 115, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2 IN COMPLEX WITH METHYL GAMMA- LINOLENYL FLUOROPHOSPHONATE
54, 5ixcB, 0.7839, 1.80, 0.183, 680, 115, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2 IN COMPLEX WITH METHYL GAMMA- LINOLENYL FLUOROPHOSPHONATE
55, 4iqhA, 0.7798, 2.25, 0.227, 128, 119, CRYSTAL STRUCTURE ANALYSIS OF DYSFERLIN C2A VARIANT 1 (C2AV1)
56, 2nq3A, 0.7782, 2.11, 0.153, 131, 118, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF HUMAN ITCHY HOMOLOG E3 UBIQUITIN PROTEIN LIGASE
57, 4p42A, 0.7775, 2.38, 0.210, 455, 119, EXTENDED-SYNAPTOTAGMIN 2 SMP - C2A - C2B DOMAINS
58, 4iqhC, 0.7773, 2.26, 0.218, 128, 119, CRYSTAL STRUCTURE ANALYSIS OF DYSFERLIN C2A VARIANT 1 (C2AV1)
59, 4ihbB, 0.7773, 2.05, 0.229, 126, 118, X-RAY STRUCTURE OF THE CANONICAL C2A DOMAIN FROM HUMAN DYSFERLIN
60, 5izrA, 0.7761, 1.85, 0.191, 674, 115, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2 IN COMPLEX WITH METHYL GAMMA- LINOLENYL FLUOROPHOSPHONATE INHIBITOR AND TERBIUM CHLORIDE
61, 4ihbC, 0.7753, 2.12, 0.229, 127, 118, X-RAY STRUCTURE OF THE CANONICAL C2A DOMAIN FROM HUMAN DYSFERLIN
62, 5iz5A, 0.7741, 1.92, 0.174, 757, 115, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2
63, 4ihbD, 0.7716, 2.13, 0.229, 128, 118, X-RAY STRUCTURE OF THE CANONICAL C2A DOMAIN FROM HUMAN DYSFERLIN
64, 3b7yB, 0.7716, 3.11, 0.270, 146, 126, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF THE E3 UBIQUITIN- PROTEIN LIGASE NEDD4
65, 4ihbA, 0.7710, 2.14, 0.229, 126, 118, X-RAY STRUCTURE OF THE CANONICAL C2A DOMAIN FROM HUMAN DYSFERLIN
66, 5izrD, 0.7706, 1.85, 0.175, 664, 114, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2 IN COMPLEX WITH METHYL GAMMA- LINOLENYL FLUOROPHOSPHONATE INHIBITOR AND TERBIUM CHLORIDE
67, 3b7yA, 0.7700, 2.81, 0.277, 144, 119, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF THE E3 UBIQUITIN- PROTEIN LIGASE NEDD4
68, 5a50B, 0.7687, 2.12, 0.241, 165, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS ZN AND PHOPHO CHOLINE
69, 2cjsA, 0.7682, 2.23, 0.157, 163, 115, STRUCTURAL BASIS FOR A MUNC13-1 DIMERIC   - MUNC13-1 - RIM HETERODIMER SWITCH: C2-DOMAINS AS VERSATILE PROTEIN- PROTEIN INTERACTION MODULES
70, 5a51B, 0.7677, 2.08, 0.250, 165, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS AND PHOPHATIDYL SERINE
71, 4v29B, 0.7674, 2.10, 0.250, 165, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS
72, 4ihbF, 0.7671, 2.22, 0.229, 126, 118, X-RAY STRUCTURE OF THE CANONICAL C2A DOMAIN FROM HUMAN DYSFERLIN
73, 5izrC, 0.7661, 1.83, 0.177, 659, 113, HUMAN GIVD CYTOSOLIC PHOSPHOLIPASE A2 IN COMPLEX WITH METHYL GAMMA- LINOLENYL FLUOROPHOSPHONATE INHIBITOR AND TERBIUM CHLORIDE
74, 5a51A, 0.7657, 2.14, 0.241, 165, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS AND PHOPHATIDYL SERINE
75, 3m7fB, 0.7656, 2.79, 0.269, 135, 119, CRYSTAL STRUCTURE OF THE NEDD4 C2/GRB10 SH2 COMPLEX
76, 2dmhA, 0.7654, 2.20, 0.254, 140, 118, SOLUTION STRUCTURE OF THE FIRST C2 DOMAIN OF HUMAN MYOFERLIN
77, 2cjsB, 0.7651, 2.06, 0.158, 156, 114, STRUCTURAL BASIS FOR A MUNC13-1 DIMERIC   - MUNC13-1 - RIM HETERODIMER SWITCH: C2-DOMAINS AS VERSATILE PROTEIN- PROTEIN INTERACTION MODULES
78, 5a4xB, 0.7648, 2.14, 0.250, 163, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS AND ZN
79, 4v29A, 0.7639, 2.16, 0.241, 165, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS
80, 4rj9A, 0.7637, 2.01, 0.237, 161, 114, STRUCTURE OF A PLANT SPECIFIC C2 DOMAIN PROTEIN OSGAP1 FROM RICE
81, 3l9bA, 0.7637, 2.08, 0.172, 126, 116, CRYSTAL STRUCTURE OF RAT OTOFERLIN C2A
82, 2jqzA, 0.7632, 2.72, 0.197, 131, 122, SOLUTION STRUCTURE OF THE C2 DOMAIN OF HUMAN SMURF2
83, 5a50A, 0.7628, 2.17, 0.241, 165, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS ZN AND PHOPHO CHOLINE
84, 5a52A, 0.7618, 1.94, 0.212, 154, 113, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR1 IN COMPLEX WITH ONE CALCIUM ION
85, 5a4xA, 0.7618, 2.18, 0.250, 158, 116, THE CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA CAR4 IN COMPLEX WITH TWO CALCIUM IONS AND ZN
86, 2cjtD, 0.7563, 2.14, 0.161, 127, 112, STRUCTURAL BASIS FOR A MUNC13-1 DIMERIC   - MUNC13-1 - RIM HETERODIMER SWITCH: C2-DOMAINS AS VERSATILE PROTEIN- PROTEIN INTERACTION MODULES
87, 5ue8A, 0.7550, 1.45, 0.243, 847, 107, THE CRYSTAL STRUCTURE OF MUNC13-1 C1C2BMUN DOMAIN
88, 2cjtC, 0.7535, 2.21, 0.170, 127, 112, STRUCTURAL BASIS FOR A MUNC13-1 DIMERIC   - MUNC13-1 - RIM HETERODIMER SWITCH: C2-DOMAINS AS VERSATILE PROTEIN- PROTEIN INTERACTION MODULES
89, 5fi4A, 0.7534, 3.05, 0.160, 1009, 125, DISCOVERY OF IMIDAZO[12-A]-PYRIDINE INHIBITORS OF PAN-PI3 KINASES THAT ARE EFFICACIOUS IN A MOUSE XENOGRAFT MODEL
90, 4zopA, 0.7534, 2.97, 0.160, 1000, 125, CO-CRYSTAL STRUCTURE OF LIPID KINASE PI3K ALPHA WITH A SELECTIVE PHOSPHATIDYLINOSITOL-3 KINASE ALPHA INHIBITOR
91, 4jpsA, 0.7534, 3.16, 0.159, 999, 126, CO-CRYSTAL STRUCTURES OF THE LIPID KINASE PI3K ALPHA WITH PAN AND ISOFORM SELECTIVE INHIBITORS
92, 4l2yA, 0.7533, 3.05, 0.160, 991, 125, CRYSTAL STRUCTURE OF P110ALPHA COMPLEXED WITH NISH2 OF P85ALPHA AND COMPOUND 9D
93, 5xgiA, 0.7527, 3.05, 0.160, 1013, 125, CRYSTAL STRUCTURE OF PI3K COMPLEX WITH AN INHIBITOR 
94, 4wafA, 0.7525, 3.05, 0.160, 1017, 125, CRYSTAL STRUCTURE OF A NOVEL TETRAHYDROPYRAZOLO[15-A]PYRAZINE IN AN ENGINEERED PI3K ALPHA
95, 5vlrA, 0.7521, 2.88, 0.154, 926, 123, CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A TRIFLUORO-ETHYL- PYRAZOL-PYROLOTRIAZINE INHIBITOR
96, 1bciA, 0.7518, 2.49, 0.150, 123, 120, C2 DOMAIN OF CYTOSOLIC PHOSPHOLIPASE A2 NMR MINIMIZED AVERAGE STRUCTURE
97, 5uk8A, 0.7512, 3.04, 0.160, 1008, 125, THE CO-STRUCTURE OF (R)-4-(6-(1-(CYCLOPROPYLSULFONYL)CYCLOPROPYL)-2- (1H-INDOL-4-YL)PYRIMIDIN-4-YL)-3-METHYLMORPHOLINE AND A RATIONALLY DESIGNED PI3K-ALPHA MUTANT THAT MIMICS ATR
98, 5itdA, 0.7507, 3.04, 0.160, 995, 125, CRYSTAL STRUCTURE OF PI3K ALPHA WITH PI3K DELTA INHIBITOR
99, 4l1bA, 0.7505, 3.08, 0.160, 994, 125, CRYSTAL STRUCTURE OF P110ALPHA COMPLEXED WITH NISH2 OF P85ALPHA
100, 5ul1A, 0.7499, 3.05, 0.160, 1000, 125, THE CO-STRUCTURE OF 3-AMINO-6-(4-((1-(DIMETHYLAMINO)PROPAN-2-YL) SULFONYL)PHENYL)-N-PHENYLPYRAZINE-2-CARBOXAMIDE AND A RATIONALLY DESIGNED PI3K-ALPHA MUTANT THAT MIMICS ATR
101, 5ukjA, 0.7498, 3.06, 0.160, 1009, 125, THE CO-STRUCTURE OF NN-DIMETHYL-4-[(6R)-6-METHYL-5-(1H-PYRROLO[23- B]PYRIDIN-4-YL)-4567-TETRAHYDROPYRAZOLO[15- A]PYRAZIN-3- YL]BENZENESULFONAMIDE AND A RATIONALLY DESIGNED PI3K-ALPHA MUTANT THAT MIMICS ATR
102, 5xgjA, 0.7495, 3.10, 0.160, 980, 125, CRYSTAL STRUCTURE OF PI3K COMPLEX WITH AN INHIBITOR 
103, 4l23A, 0.7492, 3.08, 0.160, 1014, 125, CRYSTAL STRUCTURE OF P110ALPHA COMPLEXED WITH NISH2 OF P85ALPHA AND PI-103
104, 5xghA, 0.7484, 3.11, 0.160, 993, 125, CRYSTAL STRUCTURE OF PI3K COMPLEX WITH AN INHIBITOR 
105, 2enqA, 0.7479, 3.11, 0.152, 158, 125, SOLUTION STRUCTURE OF THE C2 DOMAIN FROM HUMAN PI3-KINASE P110 SUBUNIT ALPHA
106, 4yknA, 0.7476, 3.00, 0.154, 1205, 123, PI3K ALPHA LIPID KINASE WITH ACTIVE SITE INHIBITOR
107, 3nsjA, 0.7447, 2.10, 0.195, 530, 113, THE X-RAY CRYSTAL STRUCTURE OF LYMPHOCYTE PERFORIN
108, 2cjtA, 0.7447, 2.25, 0.153, 121, 111, STRUCTURAL BASIS FOR A MUNC13-1 DIMERIC   - MUNC13-1 - RIM HETERODIMER SWITCH: C2-DOMAINS AS VERSATILE PROTEIN- PROTEIN INTERACTION MODULES
109, 5ubtA, 0.7446, 3.01, 0.154, 911, 123, CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1- YL)PHENYL)PYRROLO[21-F][124] TRIAZIN-4-AMINE DERIVIATINE
110, 2cjtB, 0.7441, 2.25, 0.153, 121, 111, STRUCTURAL BASIS FOR A MUNC13-1 DIMERIC   - MUNC13-1 - RIM HETERODIMER SWITCH: C2-DOMAINS AS VERSATILE PROTEIN- PROTEIN INTERACTION MODULES
111, 5m6uA, 0.7433, 2.76, 0.158, 916, 120, HUMAN PI3KDELTA IN COMPLEX WITH LASW1579
112, 2yoaB, 0.7430, 2.45, 0.250, 149, 112, SYNAPTOTAGMIN-1 C2B DOMAIN WITH PHOSPHOSERINE
113, 5vfgA, 0.7429, 2.58, 0.259, 151, 112, SYNAPTOTAGMIN 1 C2B DOMAIN; LEAD-BOUND (HIGH OCCUPANCY) 
114, 5ccjB, 0.7412, 2.60, 0.250, 151, 112, CRYSTAL STRUCTURE OF THE QUINTUPLE MUTANT OF THE SYNAPTOTAGMIN-1 C2B DOMAIN
115, 5t8fA, 0.7406, 2.99, 0.164, 921, 122, P110DELTA/P85ALPHA WITH TASELISIB (GDC-0032)
116, 1uovA, 0.7400, 2.66, 0.250, 149, 112, CALCIUM BINDING DOMAIN C2B
117, 5ccjA, 0.7392, 2.58, 0.250, 148, 112, CRYSTAL STRUCTURE OF THE QUINTUPLE MUTANT OF THE SYNAPTOTAGMIN-1 C2B DOMAIN
118, 5ccjC, 0.7390, 2.55, 0.250, 148, 112, CRYSTAL STRUCTURE OF THE QUINTUPLE MUTANT OF THE SYNAPTOTAGMIN-1 C2B DOMAIN
119, 5dxuA, 0.7389, 3.00, 0.164, 922, 122, P110DELTA/P85ALPHA WITH GDC-0326
120, 2yoaA, 0.7389, 2.56, 0.259, 149, 112, SYNAPTOTAGMIN-1 C2B DOMAIN WITH PHOSPHOSERINE
121, 1uowA, 0.7384, 2.67, 0.250, 156, 112, CALCIUM BINDING DOMAIN C2B
122, 1tjxA, 0.7384, 2.67, 0.250, 156, 112, CRYSTALLOGRAPHIC IDENTIFICATION OF CA2+ COORDINATION SITES IN SYNAPTOTAGMIN I C2B DOMAIN
123, 5ccjD, 0.7378, 2.63, 0.250, 152, 112, CRYSTAL STRUCTURE OF THE QUINTUPLE MUTANT OF THE SYNAPTOTAGMIN-1 C2B DOMAIN
124, 5ccgE, 0.7373, 2.63, 0.250, 278, 112, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM)
125, 1tjmA, 0.7369, 2.68, 0.250, 156, 112, CRYSTALLOGRAPHIC IDENTIFICATION OF SR2+ COORDINATION SITE IN SYNAPTOTAGMIN I C2B DOMAIN
126, 5kj7E, 0.7367, 2.68, 0.250, 278, 112, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM) - FROM XFEL DIFFRACTION
127, 4y1tA, 0.7367, 2.12, 0.204, 126, 113, STRUCTURAL BASIS FOR CA2+-MEDIATED INTERACTION OF THE PERFORIN C2 DOMAIN WITH LIPID MEMBRANES
128, 5kj8K, 0.7364, 2.65, 0.250, 278, 112, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM) - FROM SYNCHROTRON DIFFRACTION
129, 2r83B, 0.7361, 2.60, 0.250, 279, 112, CRYSTAL STRUCTURE ANALYSIS OF HUMAN SYNAPTOTAGMIN 1 C2A-C2B
130, 2r83A, 0.7360, 2.60, 0.250, 279, 112, CRYSTAL STRUCTURE ANALYSIS OF HUMAN SYNAPTOTAGMIN 1 C2A-C2B
131, 5ae9A, 0.7352, 2.90, 0.150, 858, 120, CRYSTAL STRUCTURE OF MOUSE PI3 KINASE DELTA IN COMPLEX WITH GSK2292767
132, 5vffA, 0.7350, 2.50, 0.264, 149, 110, SYNAPTOTAGMIN 1 C2B DOMAIN; LEAD-BOUND (LOW OCCUPANCY) 
133, 5kj8E, 0.7348, 2.67, 0.250, 278, 112, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM) - FROM SYNCHROTRON DIFFRACTION
134, 6ez6A, 0.7345, 2.88, 0.158, 863, 120, PI3 KINASE DELTA IN COMPLEX WITH METHYL 5-(4-(5-((4- ISOPROPYLPIPERAZIN-1-YL)METHYL)OXAZOL-2-YL)-1H-INDAZOL-6-YL)-2- METHOXYNICOTINATE
135, 6eyzA, 0.7344, 2.89, 0.150, 862, 120, PI3 KINASE DELTA IN COMPLEX WITH 4-FLUOROPHENYL 5-(4-(5-((4- ISOPROPYLPIPERAZIN-1-YL)METHYL)OXAZOL-2-YL)-1H-INDAZOL-6-YL)-2- METHOXYNICOTINATE
136, 5kj7K, 0.7344, 2.68, 0.250, 278, 112, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM) - FROM XFEL DIFFRACTION
137, 2qz5A, 0.7339, 3.07, 0.153, 152, 124, CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF AIDA
138, 5ccgK, 0.7338, 2.68, 0.250, 278, 112, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM)
139, 4v11A, 0.7338, 2.69, 0.259, 150, 112, STRUCTURE OF SYNAPTOTAGMIN-1 WITH SV2A PEPTIDE PHOSPHORYLATED AT THR84
140, 4ovuA, 0.7335, 3.24, 0.160, 1044, 125, CRYSTAL STRUCTURE OF P110ALPHA IN COMPLEX WITH NISH2 OF P85ALPHA
141, 2qz5B, 0.7327, 2.97, 0.154, 154, 123, CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF AIDA
142, 5l72A, 0.7322, 2.92, 0.150, 858, 120, PI3 KINASE DELTA IN COMPLEX WITH N-[6-(5-METHANESULFONAMIDO-6- METHOXYPYRIDIN-3-YL)-13-DIHYDRO-2-BENZOFURAN-4-YL]-2-(MORPHOLIN-4- YL)ACETAMIDE
143, 5ae8A, 0.7322, 2.91, 0.150, 856, 120, CRYSTAL STRUCTURE OF MOUSE PI3 KINASE DELTA IN COMPLEX WITH GSK2269557
144, 5dxhA, 0.7320, 3.02, 0.156, 989, 122, P110ALPHA/P85ALPHA WITH COMPOUND 5
145, 1dsyA, 0.7320, 2.81, 0.202, 137, 114, C2 DOMAIN FROM PROTEIN KINASE C (ALPHA) COMPLEXED WITH CA2+ AND PHOSPHATIDYLSERINE
146, 2uzpA, 0.7314, 3.09, 0.198, 141, 116, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF HUMAN PROTEIN KINASE C GAMMA.
147, 6ewpA, 0.7304, 2.80, 0.129, 166, 124, MUS MUSCULUS CEP120 THIRD C2 DOMAIN (C2C) 
148, 4l1lA, 0.7301, 2.91, 0.211, 138, 114, RAT PKC C2 DOMAIN BOUND TO CD
149, 6ankB, 0.7298, 2.31, 0.222, 263, 108, SYNAPTOTAGMIN-7 C2A- AND C2B-DOMAINS
150, 2uzpB, 0.7298, 2.95, 0.200, 141, 115, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF HUMAN PROTEIN KINASE C GAMMA.
151, 5ug7A, 0.7294, 2.21, 0.204, 126, 113, CALCIUM BOUND PERFORIN C2 DOMAIN - T431D
152, 4tv3A, 0.7293, 2.95, 0.143, 879, 119, ISOLATED P110A SUBUNIT OF PI3KA PROVIDES A PLATFORM FOR STRUCTURE- BASED DRUG DESIGN
153, 5swgA, 0.7290, 3.04, 0.163, 1041, 123, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 5 AND 21
154, 6ewpC, 0.7289, 2.89, 0.129, 167, 124, MUS MUSCULUS CEP120 THIRD C2 DOMAIN (C2C) 
155, 2uzpC, 0.7286, 3.12, 0.198, 141, 116, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF HUMAN PROTEIN KINASE C GAMMA.
156, 5cciE, 0.7282, 2.75, 0.250, 280, 112, STRUCTURE OF THE MG2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (SHORT UNIT CELL FORM)
157, 4qamB, 0.7282, 2.68, 0.108, 175, 120, CRYSTAL STRUCTURE OF THE RPGR RCC1-LIKE DOMAIN IN COMPLEX WITH THE RPGR-INTERACTING DOMAIN OF RPGRIP1
158, 5cchE, 0.7281, 2.73, 0.250, 280, 112, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (SHORT UNIT CELL FORM)
159, 3rdjA, 0.7281, 2.55, 0.214, 137, 112, RAT PKC C2 DOMAIN APO
160, 3twyA, 0.7279, 2.61, 0.214, 137, 112, RAT PKC C2 DOMAIN BOUND TO PB
161, 3gpeA, 0.7276, 2.90, 0.202, 137, 114, CRYSTAL STRUCTURE ANALYSIS OF PKC (ALPHA)-C2 DOMAIN COMPLEXED WITH CA2+ AND PTDINS(45)P2
162, 3n5aA, 0.7272, 2.26, 0.222, 138, 108, SYNAPTOTAGMIN-7 C2B-DOMAIN CALCIUM BOUND
163, 4tuuA, 0.7271, 2.96, 0.143, 879, 119, ISOLATED P110A SUBUNIT OF PI3KA PROVIDES A PLATFORM FOR STRUCTURE- BASED DRUG DESIGN
164, 1wfjA, 0.7270, 2.62, 0.207, 136, 116, C2 DOMAIN-CONTAINING PROTEIN FROM PUTATIVE ELICITOR- RESPONSIVE GENE
165, 5cciF, 0.7268, 2.26, 0.266, 268, 109, STRUCTURE OF THE MG2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (SHORT UNIT CELL FORM)
166, 5swoA, 0.7265, 3.05, 0.163, 1050, 123, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 4 AND 19
167, 5cchF, 0.7265, 2.37, 0.264, 266, 110, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (SHORT UNIT CELL FORM)
168, 1a25A, 0.7263, 2.59, 0.234, 132, 111, C2 DOMAIN FROM PROTEIN KINASE C (BETA)
169, 5swpA, 0.7262, 3.24, 0.161, 1058, 124, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 6 AND 24
170, 1e7uA, 0.7261, 3.06, 0.140, 872, 121, STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN LY294002 QUERCETIN MYRICETIN AND STAUROSPORINE
171, 4ldcA, 0.7257, 2.45, 0.255, 149, 110, CRYSTAL STRUCTURE OF DOC2B C2B DOMAIN
172, 6ankA, 0.7256, 2.28, 0.224, 262, 107, SYNAPTOTAGMIN-7 C2A- AND C2B-DOMAINS
173, 4ovvA, 0.7254, 3.13, 0.164, 1042, 122, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH DIC4-PIP2
174, 1a25B, 0.7252, 2.40, 0.236, 132, 110, C2 DOMAIN FROM PROTEIN KINASE C (BETA)
175, 5ue8B, 0.7249, 1.53, 0.243, 838, 103, THE CRYSTAL STRUCTURE OF MUNC13-1 C1C2BMUN DOMAIN
176, 2qzqA, 0.7245, 3.01, 0.140, 149, 121, CRYSTAL STRUCTURE OF C-TERMINAL OF AIDA
177, 5swtA, 0.7241, 3.07, 0.163, 1057, 123, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 17 AND 27
178, 5sxkA, 0.7237, 3.08, 0.163, 1053, 123, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 18
179, 6ewpB, 0.7233, 2.86, 0.122, 171, 123, MUS MUSCULUS CEP120 THIRD C2 DOMAIN (C2C) 
180, 5t2lA, 0.7232, 2.91, 0.161, 830, 118, MPI3KD IN COMPLEX WITH 7L
181, 2wxgA, 0.7232, 2.89, 0.153, 835, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH SW13.
182, 5swrA, 0.7230, 3.14, 0.163, 1051, 123, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 20 AND 26
183, 3pfqA, 0.7223, 2.87, 0.219, 520, 114, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
184, 1k5wA, 0.7219, 2.79, 0.250, 148, 112, THREE-DIMENSIONAL STRUCTURE OF THE SYNAPTOTAGMIN 1 C2B- DOMAIN: SYNAPTOTAGMIN 1 AS A PHOSPHOLIPID BINDING MACHINE
185, 5t28A, 0.7218, 2.91, 0.161, 822, 118, MPI3KD IN COMPLEX WITH 5K
186, 2x38A, 0.7218, 2.90, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH IC87114.
187, 5sxaA, 0.7217, 3.13, 0.164, 1049, 122, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 10
188, 5lowC, 0.7217, 2.52, 0.227, 144, 110, STRUCTURE OF THE CA2+-BOUND RABPHILIN 3A C2B DOMAIN SNAP25 COMPLEX (P21 SPACE GROUP)
189, 5t0sA, 0.7216, 2.53, 0.255, 151, 110, SYNAPTOTAGMIN 1 C2B DOMAIN CADMIUM-BOUND
190, 2wxlA, 0.7211, 2.90, 0.153, 823, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH ZSTK474.
191, 2wxfA, 0.7208, 2.89, 0.153, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH PIK-39.
192, 1e8wA, 0.7208, 3.24, 0.140, 851, 121, STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN LY294002 QUERCETIN MYRICETIN AND STAUROSPORINE
193, 5t0rA, 0.7207, 2.11, 0.271, 125, 107, SYNAPTOTAGMIN 1 C2A DOMAIN CADMIUM-BOUND
194, 5sxiA, 0.7207, 3.15, 0.163, 1040, 123, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 13
195, 2n1tE, 0.7206, 2.75, 0.250, 156, 112, DYNAMIC BINDING MODE OF A SYNAPTOTAGMIN-1-SNARE COMPLEX IN SOLUTION
196, 1rsyA, 0.7206, 2.15, 0.271, 135, 107, STRUCTURE OF THE FIRST C2-DOMAIN OF SYNAPTOTAGMIN I: A NOVEL CA2+(SLASH)PHOSPHOLIPID BINDING FOLD
197, 5sxbA, 0.7205, 3.11, 0.154, 1056, 123, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 23
198, 5kj8F, 0.7204, 2.63, 0.261, 274, 111, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM) - FROM SYNCHROTRON DIFFRACTION
199, 5w5cF, 0.7203, 2.80, 0.250, 261, 112, CRYSTAL STRUCTURE OF THE PRIMED SNARE-COMPLEXIN-SYNAPTOTAGMIN-1 C2AB COMPLEX
200, 5kj7F, 0.7203, 2.67, 0.261, 274, 111, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM) - FROM XFEL DIFFRACTION
201, 2wxiA, 0.7200, 2.90, 0.161, 815, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH SW30.
202, 1bynA, 0.7197, 2.21, 0.269, 128, 108, SOLUTION STRUCTURE OF THE CALCIUM-BOUND FIRST C2-DOMAIN OF SYNAPTOTAGMIN I
203, 2wxkA, 0.7196, 2.90, 0.169, 835, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH INK666.
204, 5ccgF, 0.7195, 2.52, 0.264, 274, 110, STRUCTURE OF THE CA2+-BOUND SYNAPTOTAGMIN-1 SNARE COMPLEX (LONG UNIT CELL FORM)
205, 5ngbA, 0.7190, 2.91, 0.161, 816, 118, X-RAY DIFFRACTION CRYSTAL STRUCTURE OF THE MURINE PI3K P110DELTA IN COMPLEX WITH A PAN INHIBITOR
206, 5w5dF, 0.7187, 2.78, 0.250, 152, 112, CRYSTAL STRUCTURE OF THE PRIMED SNARE-COMPLEXIN-SYNAPTOTAGMIN-1 C2B COMPLEX
207, 2wxoA, 0.7187, 2.92, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH AS5.
208, 2wxhA, 0.7186, 2.90, 0.153, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH SW14.
209, 4y1sA, 0.7185, 2.08, 0.202, 122, 109, STRUCTURAL BASIS FOR CA2+-MEDIATED INTERACTION OF THE PERFORIN C2 DOMAIN WITH LIPID MEMBRANES
210, 3w57A, 0.7183, 2.25, 0.243, 111, 111, STRUCTURE OF A C2 DOMAIN
211, 6ftnA, 0.7181, 2.95, 0.153, 827, 118, MPI3KD IN COMPLEX WITH AZ2 
212, 5h4zB, 0.7181, 2.18, 0.234, 128, 107, CRYSTAL STRUCTURE OF S202G MUTANT OF HUMAN SYT-5 C2A DOMAIN
213, 4fa6A, 0.7179, 3.22, 0.150, 842, 120, DESIGN AND SYNTHESIS OF A NOVEL PYRROLIDINYL PYRIDO PYRIMIDINONE DERIVATIVE AS A POTENT INHIBITOR OF PI3KA AND MTOR
214, 2wxpA, 0.7179, 2.93, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH GDC-0941.
215, 3w57B, 0.7177, 2.27, 0.243, 111, 111, STRUCTURE OF A C2 DOMAIN
216, 5h4zA, 0.7174, 2.18, 0.234, 129, 107, CRYSTAL STRUCTURE OF S202G MUTANT OF HUMAN SYT-5 C2A DOMAIN
217, 3hn8C, 0.7174, 2.71, 0.257, 279, 113, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN
218, 2wxqA, 0.7174, 2.92, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH AS15.
219, 5sx8A, 0.7173, 3.08, 0.164, 1052, 122, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 12 AND 15
220, 3hn8B, 0.7173, 2.70, 0.257, 279, 113, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN
221, 3hn8A, 0.7173, 2.71, 0.257, 279, 113, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN
222, 2wxmA, 0.7172, 2.94, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH DL06.
223, 5i4uA, 0.7170, 2.93, 0.154, 815, 117, THE CRYSTAL STRUCTURE OF PI3KDELTA WITH COMPOUND 34
224, 5h4yA, 0.7170, 2.30, 0.241, 126, 108, CRYSTAL STRUCTURE OF HUMAN SYNAPTOTAGMIN 5 C2A DOMAIN
225, 5lobA, 0.7169, 2.24, 0.224, 138, 107, STRUCTURE OF THE CA2+-BOUND RABPHILIN3A C2B- SNAP25 COMPLEX (C2 SPACE GROUP)
226, 3s2aA, 0.7169, 3.08, 0.161, 834, 118, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH A QUINOLINE INHIBITOR
227, 2v4lA, 0.7168, 3.20, 0.142, 844, 120, COMPLEX OF HUMAN PHOSPHOINOSITIDE 3-KINASE CATALYTIC SUBUNIT GAMMA (P110 GAMMA) WITH PIK-284
228, 2wxjA, 0.7166, 2.94, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH INK654.
229, 5t7fA, 0.7155, 2.98, 0.153, 819, 118, PI3KDELTA IN COMPLEX WITH THE INHIBITOR GS-643624
230, 3hhmA, 0.7151, 3.30, 0.163, 1032, 123, CRYSTAL STRUCTURE OF P110ALPHA H1047R MUTANT IN COMPLEX WITH NISH2 OF P85ALPHA AND THE DRUG WORTMANNIN
231, 2b3rB, 0.7150, 2.07, 0.160, 124, 106, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF CLASS II PHOSPHATIDYLINOSITIDE 3-KINASE C2
232, 5lo8A, 0.7149, 2.32, 0.231, 140, 108, THE C2B DOMAIN OF RABPHILIN 3A IN COMPLEX WITH PI(45)P2
233, 4dk5A, 0.7148, 3.12, 0.153, 834, 118, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH A PYRIDYL- TRIAZINE INHIBITOR
234, 5lowI, 0.7145, 2.51, 0.227, 145, 110, STRUCTURE OF THE CA2+-BOUND RABPHILIN 3A C2B DOMAIN SNAP25 COMPLEX (P21 SPACE GROUP)
235, 4dnlA, 0.7144, 3.08, 0.212, 133, 113, CRYSTAL STRUCTURE OF A C2 DOMAIN OF A PROTEIN KINASE C ALPHA (PRKCA) FROM HOMO SAPIENS AT 1.90 A RESOLUTION
236, 5lowB, 0.7141, 2.45, 0.229, 144, 109, STRUCTURE OF THE CA2+-BOUND RABPHILIN 3A C2B DOMAIN SNAP25 COMPLEX (P21 SPACE GROUP)
237, 3l54A, 0.7141, 3.39, 0.165, 837, 121, STRUCTURE OF PI3K GAMMA WITH INHIBITOR
238, 5sxcA, 0.7138, 3.14, 0.165, 1038, 121, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 8
239, 5kaeA, 0.7137, 3.10, 0.144, 840, 118, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH QUINOLINE- CONTAINING INHIBITOR 5G
240, 2b3rA, 0.7137, 2.11, 0.160, 124, 106, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF CLASS II PHOSPHATIDYLINOSITIDE 3-KINASE C2
241, 3qarA, 0.7136, 2.99, 0.145, 834, 117, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH TRIAZINE-BENZIMIDAZOLE 32
242, 4f1sA, 0.7134, 3.12, 0.144, 834, 118, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH A PYRIDYL- TRIAZINE-SULFONAMIDE INHIBITOR
243, 5sxeA, 0.7133, 3.10, 0.167, 1046, 120, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 19 AND 28
244, 3apfA, 0.7132, 3.17, 0.151, 840, 119, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH CH5039699
245, 5t8iA, 0.7131, 2.96, 0.162, 808, 117, PI3KDELTA IN COMPLEX WITH THE INHIBITOR GS-9901
246, 5lowA, 0.7131, 2.35, 0.222, 142, 108, STRUCTURE OF THE CA2+-BOUND RABPHILIN 3A C2B DOMAIN SNAP25 COMPLEX (P21 SPACE GROUP)
247, 5sxdA, 0.7128, 3.08, 0.157, 1049, 121, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 22
248, 5g55A, 0.7126, 3.20, 0.143, 847, 119, 3-QUINOLINE CARBOXAMIDES INHIBITORS OF PI3K
249, 4wwpA, 0.7125, 2.94, 0.155, 820, 116, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH PYRIDINYLQUINOLINE INHIBITOR N-{(1S)-1-[8-CHLORO-2-(2-METHYLPYRIDIN- 3-YL)QUINOLIN-3-YL]ETHYL}-9H-PURIN-6-AMINE
250, 3qaqA, 0.7125, 3.25, 0.151, 837, 119, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH TRIAZINE-BENZIMIDAZOLE 2 1
251, 3hizA, 0.7125, 3.21, 0.163, 1024, 123, CRYSTAL STRUCTURE OF P110ALPHA H1047R MUTANT IN COMPLEX WITH NISH2 OF P85ALPHA
252, 5sx9A, 0.7123, 3.08, 0.165, 1044, 121, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 14
253, 1e7vA, 0.7123, 3.29, 0.142, 850, 120, STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN LY294002 QUERCETIN MYRICETIN AND STAUROSPORINE
254, 5dxtA, 0.7118, 2.99, 0.154, 879, 117, P110ALPHA WITH GDC-0326
255, 3csfA, 0.7115, 3.27, 0.143, 839, 119, CRYSTAL STRUCTURE OF PI3K P110GAMMA CATALYTICAL DOMAIN IN COMPLEX WITH ORGANORUTHENIUM INHIBITOR DW2
256, 4flhA, 0.7113, 3.31, 0.143, 840, 119, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH AMG511
257, 4bfrB, 0.7113, 3.38, 0.148, 836, 122, DISCOVERY AND OPTIMIZATION OF PYRIMIDONE INDOLINE AMIDE PI3KBETA INHIBITORS FOR THE TREATMENT OF PHOSPHATASE AND TENSIN HOMOLOGUE (PTEN)-DEFICIENT CANCERS
258, 2cm6B, 0.7112, 2.37, 0.222, 148, 108, CRYSTAL STRUCTURE OF THE C2B DOMAIN OF RABPHILIN3A
259, 1e8xA, 0.7111, 3.24, 0.143, 841, 119, STRUCTURAL INSIGHTS INTO PHOSHOINOSITIDE 3-KINASE ENZYMATIC MECHANISM AND SIGNALLING
260, 4fjyA, 0.7108, 2.99, 0.154, 839, 117, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH QUINOLINE-INDOLINE INHIBITOR 24F
261, 5vfeB, 0.7107, 2.18, 0.274, 124, 106, SYNAPTOTAGMIN 1 C2A DOMAIN; LEAD-BOUND 
262, 5sxfA, 0.7106, 3.12, 0.165, 1023, 121, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 9
263, 2wxrA, 0.7106, 3.01, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA.
264, 2wxnA, 0.7106, 3.00, 0.161, 822, 118, THE CRYSTAL STRUCTURE OF THE MURINE CLASS IA PI 3-KINASE P110DELTA IN COMPLEX WITH DL07.
265, 5lowH, 0.7105, 2.46, 0.229, 140, 109, STRUCTURE OF THE CA2+-BOUND RABPHILIN 3A C2B DOMAIN SNAP25 COMPLEX (P21 SPACE GROUP)
266, 4fjzA, 0.7104, 2.94, 0.164, 822, 116, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH PYRROLO-PYRIDINE INHIBITOR 63
267, 5lo8B, 0.7101, 2.46, 0.222, 142, 108, THE C2B DOMAIN OF RABPHILIN 3A IN COMPLEX WITH PI(45)P2
268, 4a55A, 0.7099, 3.09, 0.167, 1001, 120, CRYSTAL STRUCTURE OF P110ALPHA IN COMPLEX WITH ISH2 OF P85ALPHA AND THE INHIBITOR PIK-108
269, 4weeA, 0.7098, 2.30, 0.271, 135, 107, HIGH-RESOLUTION STRUCTURE OF SYNAPTOTAGMIN 1 C2A
270, 5t27A, 0.7096, 3.00, 0.154, 819, 117, MPI3KD IN COMPLEX WITH 5D
271, 4wwnA, 0.7096, 3.09, 0.154, 831, 117, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH (S)-N-(1-(7- FLUORO-2-(PYRIDIN-2-YL)QUINOLIN-3-YL)ETHYL)-9H-PURIN-6-AMINE AMG319 INHIBITOR
272, 3f04A, 0.7096, 2.33, 0.271, 136, 107, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN I C2A DOMAIN
273, 3f01A, 0.7091, 2.31, 0.271, 143, 107, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN I C2A DOMAIN WITH CU(II)
274, 5t7fB, 0.7087, 2.98, 0.154, 816, 117, PI3KDELTA IN COMPLEX WITH THE INHIBITOR GS-643624
275, 5lobC, 0.7086, 2.33, 0.224, 138, 107, STRUCTURE OF THE CA2+-BOUND RABPHILIN3A C2B- SNAP25 COMPLEX (C2 SPACE GROUP)
276, 5dxhD, 0.7082, 3.08, 0.162, 981, 117, P110ALPHA/P85ALPHA WITH COMPOUND 5
277, 4fulA, 0.7082, 2.93, 0.148, 832, 115, PI3 KINASE GAMMA BOUND TO A PYRMIDINE INHIBITOR
278, 3eneA, 0.7082, 3.22, 0.151, 843, 119, COMPLEX OF PI3K GAMMA WITH AN INHIBITOR
279, 4xe0A, 0.7078, 2.98, 0.171, 815, 117, IDELALISIB BOUND TO THE P110 SUBUNIT OF PI3K DELTA
280, 1e90A, 0.7076, 3.31, 0.143, 844, 119, STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN LY294002 QUERCETIN MYRICETIN AND STAUROSPORINE
281, 5vfeA, 0.7073, 2.14, 0.274, 125, 106, SYNAPTOTAGMIN 1 C2A DOMAIN; LEAD-BOUND 
282, 5t2iA, 0.7072, 2.97, 0.155, 820, 116, MPI3KD IN COMPLEX WITH 7K
283, 5t2mA, 0.7071, 2.95, 0.164, 820, 116, MPI3KD IN COMPLEX WITH 7M
284, 3apcA, 0.7070, 3.10, 0.154, 839, 117, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH CH5132799
285, 4ps8A, 0.7069, 3.24, 0.143, 843, 119, STRUCTURE OF PI3K GAMMA IN COMPLEX WITH N-[6-(56-DIMETHOXYPYRIDIN-3- YL)-13-BENZOTHIAZOL-2-YL]ACETAMIDE
286, 3tjpA, 0.7069, 3.13, 0.145, 840, 117, CRYSTAL STRUCTURE OF PI3K GAMMA WITH N6-(34-DIMETHOXYPHENYL)-2- MORPHOLINO-[45 -BIPYRIMIDINE]-2 6-DIAMINE
287, 5t2bA, 0.7067, 2.96, 0.164, 820, 116, MPI3KD IN COMPLEX WITH 5E
288, 5lowJ, 0.7066, 2.29, 0.226, 140, 106, STRUCTURE OF THE CA2+-BOUND RABPHILIN 3A C2B DOMAIN SNAP25 COMPLEX (P21 SPACE GROUP)
289, 3l16A, 0.7066, 3.24, 0.153, 841, 118, DISCOVERY OF (THIENOPYRIMIDIN-2-YL)AMINOPYRIMIDINES AS POTENT SELECTIVE AND ORALLY AVAILABLE PAN-PI3-KINASE AND DUAL PAN-PI3- KINASE/MTOR INHIBITORS FOR THE TREATMENT OF CANCER
290, 4ps3A, 0.7064, 3.23, 0.143, 843, 119, STRUCTURE OF PI3K GAMMA IN COMPLEX WITH 1-[6-(5-METHOXYPYRIDIN-3-YL)- 13-BENZOTHIAZOL-2-YL]-3-[2-(1-PROPYL-1H-IMIDAZOL-4-YL)ETHYL]UREA
291, 3f05A, 0.7063, 2.17, 0.276, 134, 105, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN I C2A DOMAIN WITH MN(II)
292, 3f00A, 0.7062, 2.11, 0.274, 142, 106, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN I C2A DOMAIN WITH CU(II)
293, 4ps7A, 0.7061, 3.24, 0.151, 843, 119, STRUCTURE OF PI3K GAMMA IN COMPLEX WITH N-[6-(PYRIDIN-3-YL)-13- BENZOTHIAZOL-2-YL]ACETAMIDE
294, 3r7rA, 0.7061, 3.28, 0.153, 838, 118, STRUCTURE-BASED DESIGN OF THIENOBENZOXEPIN INHIBITORS OF PI3-KINASE
295, 4anuA, 0.7056, 3.13, 0.154, 833, 117, COMPLEXES OF PI3KGAMMA WITH ISOFORM SELECTIVE INHIBITORS.
296, 5ug6A, 0.7055, 2.28, 0.211, 123, 109, PERFORIN C2 DOMAIN - T431D
297, 5edsA, 0.7053, 3.20, 0.145, 823, 117, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH BENZIMIDAZOLE INHIBITOR 5
298, 5ubrA, 0.7051, 2.91, 0.147, 887, 116, CRYSTAL STRUCTURE OF PI3K ALPHA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1- YL)PHENYL)PYRROLO[21-F][124] TRIAZIN-4-AMINE DERIVIATINE
299, 5t2dA, 0.7050, 2.98, 0.155, 820, 116, MPI3KD IN COMPLEX WITH 7J
300, 5sxjA, 0.7050, 3.18, 0.167, 1039, 120, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENT 29
301, 3ibeA, 0.7050, 3.00, 0.155, 850, 116, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR BOUND TO PI3 KINASE GAMMA
302, 3tl5A, 0.7047, 3.21, 0.153, 845, 118, DISCOVERY OF GDC-0980: A POTENT SELECTIVE AND ORALLY AVAILABLE CLASS I PHOSPHATIDYLINOSITOL 3-KINASE (PI3K)/MAMMALIAN TARGET OF RAPAMYCIN (MTOR) KINASE INHIBITOR FOR THE TREATMENT OF CANCER
303, 3zvvA, 0.7045, 3.29, 0.153, 829, 118, FRAGMENT BOUND TO PI3KINASE GAMMA
304, 3t8mA, 0.7045, 3.27, 0.153, 841, 118, RATIONAL DESIGN OF PI3K-ALPHA INHIBITORS THAT EXHIBIT SELECTIVITY OVER THE PI3K-BETA ISOFORM
305, 5t2gA, 0.7043, 2.99, 0.164, 820, 116, MPI3KD IN COMPLEX WITH 7I
306, 2chxA, 0.7042, 3.35, 0.151, 842, 119, A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-90
307, 5oq4A, 0.7041, 3.21, 0.154, 834, 117, PQR309 - A POTENT BRAIN-PENETRANT ORALLY BIOAVAILABLE PAN-CLASS I PI3K/MTOR INHIBITOR AS CLINICAL CANDIDATE IN ONCOLOGY
308, 5ncyA, 0.7041, 2.98, 0.155, 827, 116, MPI3KD IN COMPLEX WITH INH1
309, 3l13A, 0.7041, 3.25, 0.153, 841, 118, CRYSTAL STRUCTURES OF PAN-PI3-KINASE AND DUAL PAN-PI3-KINASE/MTOR INHIBITORS
310, 3fdwA, 0.7041, 2.48, 0.213, 130, 108, CRYSTAL STRUCTURE OF A C2 DOMAIN FROM HUMAN SYNAPTOTAGMIN- LIKE PROTEIN 4
311, 3nzsA, 0.7040, 3.30, 0.161, 828, 118, STRUCTURE-BASED OPTIMIZATION OF PYRAZOLO -PYRIMIDINE AND -PYRIDINE INHIBITORS OF PI3-KINASE
312, 4xz4A, 0.7039, 3.26, 0.143, 843, 119, STRUCTURE OF PI3K GAMMA IN COMPLEX WITH AN INHIBITOR
313, 1dqvA, 0.7039, 2.46, 0.278, 275, 108, CRYSTAL STRUCTURE OF SYNAPTOTAGMIN III C2A/C2B
314, 3w56A, 0.7037, 2.24, 0.250, 108, 108, STRUCTURE OF A C2 DOMAIN
315, 5nczA, 0.7036, 2.98, 0.164, 827, 116, MPI3KD IN COMPLEX WITH INH1
316, 3fdwB, 0.7036, 2.47, 0.213, 130, 108, CRYSTAL STRUCTURE OF A C2 DOMAIN FROM HUMAN SYNAPTOTAGMIN- LIKE PROTEIN 4
317, 4anxA, 0.7035, 3.12, 0.154, 833, 117, COMPLEXES OF PI3KGAMMA WITH ISOFORM SELECTIVE INHIBITORS.
318, 3dbsA, 0.7031, 3.25, 0.153, 841, 118, STRUCTURE OF PI3K GAMMA IN COMPLEX WITH GDC0941
319, 3apdA, 0.7031, 3.11, 0.147, 839, 116, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH CH5108134
320, 6c1sA, 0.7029, 3.04, 0.148, 826, 115, PHOSPHOINOSITIDE 3-KINASE GAMMA BOUND TO AN PYRROLOPYRIDINONE INHIBITOR 
321, 3rpbA, 0.7029, 2.72, 0.225, 140, 111, THE C2B-DOMAIN OF RABPHILIN: STRUCTURAL VARIATIONS IN A JANUS-FACED DOMAIN
322, 4anwA, 0.7028, 3.13, 0.154, 833, 117, COMPLEXES OF PI3KGAMMA WITH ISOFORM SELECTIVE INHIBITORS.
323, 4xx5A, 0.7027, 3.25, 0.143, 843, 119, STRUCTURE OF PI3K GAMMA IN COMPLEX WITH AN INHIBITOR
324, 4urkA, 0.7025, 3.06, 0.155, 837, 116, PI3KG IN COMPLEX WITH AZD6482
325, 4lcvC, 0.7020, 2.36, 0.231, 129, 108, CRYSTAL STRUCTURE OF DOC2B C2A DOMAIN
326, 4ezkA, 0.7020, 3.28, 0.153, 842, 118, POTENT AND SELECTIVE INHIBITORS OF PI3K-DELTA: OBTAINING ISOFORM SELECTIVITY FROM THE AFFINITY POCKET AND TRYPTOPHAN SHELF
327, 3qk0A, 0.7020, 3.06, 0.148, 820, 115, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH BENZOTHIAZOLE 82
328, 3cstA, 0.7018, 3.33, 0.144, 836, 118, CRYSTAL STRUCTURE OF PI3K P110GAMMA CATALYTICAL DOMAIN IN COMPLEX WITH ORGANORUTHENIUM INHIBITOR E5E2
329, 5lobB, 0.7017, 2.24, 0.226, 139, 106, STRUCTURE OF THE CA2+-BOUND RABPHILIN3A C2B- SNAP25 COMPLEX (C2 SPACE GROUP)
330, 4j6iA, 0.7015, 3.26, 0.144, 833, 118, DISCOVERY OF THIAZOLOBENZOXEPIN PI3-KINASE INHIBITORS THAT SPARE THE PI3-KINASE BETA ISOFORM
331, 6ewgA, 0.7012, 3.06, 0.100, 181, 120, OREOCHROMIS NILOTICUS CEP120 SECOND C2 DOMAIN (C2B) 
332, 4lt7A, 0.7011, 2.63, 0.220, 128, 109, CRYSTAL STRUCTURE OF THE C2A DOMAIN OF RABPHILIN-3A IN COMPLEX WITH A CALCIUM
333, 4anvA, 0.7007, 3.17, 0.145, 848, 117, COMPLEXES OF PI3KGAMMA WITH ISOFORM SELECTIVE INHIBITORS.
334, 1e8yA, 0.7007, 3.34, 0.144, 841, 118, STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN LY294002 QUERCETIN MYRICETIN AND STAUROSPORINE
335, 4wwoA, 0.7006, 2.83, 0.150, 814, 113, CRYSTAL STRUCTURE OF HUMAN PI3K-GAMMA IN COMPLEX WITH PHENYLQUINOLINE INHIBITOR N-{(1S)-1-[8-CHLORO-2-(3-FLUOROPHENYL)QUINOLIN-3-YL]ETHYL}- 9H-PURIN-6-AMINE
336, 4ts6A, 0.7004, 2.43, 0.198, 126, 106, CRYSTAL STRUCTURE OF THE RIM C2A DOMAIN FROM DROSOPHILA.
337, 3r7qA, 0.7001, 3.13, 0.147, 837, 116, STRUCTURE-BASED DESIGN OF THIENOBENZOXEPIN INHIBITORS OF PI3- KINASE
338, 3l17A, 0.7001, 3.28, 0.153, 841, 118, DISCOVERY OF (THIENOPYRIMIDIN-2-YL)AMINOPYRIMIDINES AS POTENT SELECTIVE AND ORALLY AVAILABLE PAN-PI3-KINASE AND DUAL PAN-PI3- KINASE/MTOR INHIBITORS FOR THE TREATMENT OF CANCER
339, 3oawA, 0.6999, 3.19, 0.147, 841, 116, 4-METHYLPTERIDINEONES AS ORALLY ACTIVE AND SELECTIVE PI3K/MTOR DUAL INHIBITORS
340, 1e8zA, 0.6999, 3.37, 0.144, 839, 118, STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN LY294002 QUERCETIN MYRICETIN AND STAUROSPORINE
341, 3zimA, 0.6997, 2.97, 0.148, 886, 115, DISCOVERY OF A POTENT AND ISOFORM-SELECTIVE TARGETED COVALENT INHIBITOR OF THE LIPID KINASE PI3KALPHA
342, 6ewhA, 0.6996, 3.05, 0.100, 181, 120, OREOCHROMIS NILOTICUS CEP120 SECOND C2 DOMAIN (C2B) G307S MUTANT 
343, 3ml9A, 0.6992, 3.17, 0.147, 847, 116, DISCOVERY OF THE HIGHLY POTENT PI3K/MTOR DUAL INHIBITOR PF-04691502 THROUGH STRUCTURE BASED DRUG DESIGN
344, 4ajwB, 0.6990, 2.90, 0.149, 792, 114, DISCOVERY AND OPTIMIZATION OF NEW BENZIMIDAZOLE- AND BENZOXAZOLE- PYRIMIDONE SELECTIVE PI3KBETA INHIBITORS FOR THE TREATMENT OF PHOSPHATASE AND TENSIN HOMOLOGUE (PTEN)-DEFICIENT CANCERS
345, 6ewlA, 0.6989, 3.15, 0.179, 136, 117, DANIO RERIO CEP120 FIRST C2 DOMAIN (C2A) 
346, 4icwA, 0.6988, 2.93, 0.172, 130, 116, N-TERMINAL C2 DOMAIN OF HUMAN CEP120
347, 1he8A, 0.6987, 2.89, 0.158, 749, 114, RAS G12V - PI 3-KINASE GAMMA COMPLEX
348, 6dgtA, 0.6986, 3.02, 0.157, 777, 115, SELECTIVE PI3K BETA INHIBITOR BOUND TO PI3K DELTA 
349, 3fbkA, 0.6984, 2.81, 0.209, 137, 110, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF THE HUMAN REGULATOR OF G-PROTEIN SIGNALING 3 ISOFORM 6 (RGP3) NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET HR5550A
350, 2chdA, 0.6984, 2.66, 0.220, 128, 109, CRYSTAL STRUCTURE OF THE C2A DOMAIN OF RABPHILIN-3A
351, 4v0iB, 0.6978, 2.89, 0.149, 792, 114, WATER NETWORK DETERMINES SELECTIVITY FOR A SERIES OF PYRIMIDONE INDOLINE AMIDE PI3KBETA INHIBITORS OVER PI3K-DELTA
352, 4g11A, 0.6978, 3.34, 0.136, 836, 118, X-RAY STRUCTURE OF PI3K-GAMMA BOUND TO A 4-(MORPHOLIN-4-YL)- (6-OXO-1 6-DIHYDROPYRIMIDIN-2-YL)AMIDE INHIBITOR
353, 2cm6A, 0.6978, 2.12, 0.231, 149, 104, CRYSTAL STRUCTURE OF THE C2B DOMAIN OF RABPHILIN3A
354, 4hleA, 0.6976, 3.29, 0.136, 828, 118, COMPOUND 21 (1-ALKYL-SUBSTITUTED 124-TRIAZOLES)
355, 3fbkB, 0.6975, 2.88, 0.200, 137, 110, CRYSTAL STRUCTURE OF THE C2 DOMAIN OF THE HUMAN REGULATOR OF G-PROTEIN SIGNALING 3 ISOFORM 6 (RGP3) NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET HR5550A
356, 4np9A, 0.6969, 2.54, 0.222, 128, 108, STRUCTURE OF RABPHILIN C2A DOMAIN BOUND TO IP3
357, 3ps6A, 0.6968, 3.20, 0.147, 841, 116, QUINAZOLINES WITH INTRA-MOLECULAR HYDROGEN BONDING SCAFFOLD (IMHBS) AS PI3K/MTOR DUAL INHIBITORS.
358, 4ezlA, 0.6958, 3.38, 0.144, 834, 118, POTENT AND SELECTIVE INHIBITORS OF PI3K-DELTA: OBTAINING ISOFORM SELECTIVITY FROM THE AFFINITY POCKET AND TRYPTOPHAN SHELF
359, 3przA, 0.6957, 3.11, 0.148, 844, 115, QUINAZOLINES WITH INTRA-MOLECULAR HYDROGEN BONDING SCAFFOLD (IMHBS) AS PI3K/MTOR DUAL INHIBITORS.
360, 3preA, 0.6955, 3.22, 0.147, 839, 116, QUINAZOLINES WITH INTRA-MOLECULAR HYDROGEN BONDING SCAFFOLD (IMHBS) AS PI3K/MTOR DUAL INHIBITORS.
361, 4ezjA, 0.6954, 3.44, 0.153, 834, 118, POTENT AND SELECTIVE INHIBITORS OF PI3K-DELTA: OBTAINING ISOFORM SELECTIVITY FROM THE AFFINITY POCKET AND TRYPTOPHAN SHELF
362, 1w15A, 0.6953, 2.28, 0.214, 132, 103, RAT SYNAPTOTAGMIN 4 C2B DOMAIN IN THE PRESENCE OF CALCIUM
363, 4gb9A, 0.6952, 3.46, 0.153, 840, 118, POTENT AND HIGHLY SELECTIVE BENZIMIDAZOLE INHIBITORS OF PI3K-DELTA
364, 4fadA, 0.6952, 3.24, 0.147, 839, 116, DESIGN AND SYNTHESIS OF A NOVEL PYRROLIDINYL PYRIDO PYRIMIDINONE DERIVATIVE AS A POTENT INHIBITOR OF PI3KA AND MTOR
365, 4lcvD, 0.6950, 2.49, 0.224, 126, 107, CRYSTAL STRUCTURE OF DOC2B C2A DOMAIN
366, 4ns0A, 0.6948, 2.56, 0.222, 128, 108, THE C2A DOMAIN OF RABPHILIN 3A IN COMPLEX WITH PI(45)P2
367, 6audA, 0.6947, 3.37, 0.154, 840, 117, PI3K-GAMMA K802T IN COMPLEX WITH CPD 8 10-((1-(TERT-BUTYL)PIPERIDIN-4- YL)SULFINYL)-2-(1-ISOPROPYL-1H-124-TRIAZOL-5-YL)-56- DIHYDROBENZO[F]IMIDAZO[12-D][14]OXAZEPINE
368, 4icxB, 0.6947, 2.93, 0.165, 129, 115, N-TERMINAL C2 DOMAIN OF HUMAN CEP120
369, 4fhkA, 0.6946, 3.08, 0.149, 819, 114, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH IMIDAZOPYRIDAZINE 19E
370, 3lj3A, 0.6946, 3.10, 0.149, 829, 114, PI3-KINASE-GAMMA WITH A PYRROLOPYRIDINE-BENZOFURAN INHIBITOR
371, 4fhjA, 0.6945, 3.06, 0.149, 819, 114, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH IMIDAZOPYRIDINE 2
372, 6anjA, 0.6943, 2.71, 0.275, 138, 109, SYNAPTOTAGMIN-7 C2A DOMAIN
373, 6fljA, 0.6939, 2.93, 0.174, 127, 115, CRYSTAL STRUCTURE OF CEP120 C2A_K76A MUTANT
374, 3dpdA, 0.6939, 2.99, 0.149, 846, 114, ACHIEVING MULTI-ISOFORM PI3K INHIBITION IN A SERIES OF SUBSTITUTED 34-DIHYDRO-2H-BENZO[14]OXAZINES
375, 4lcvB, 0.6938, 2.66, 0.227, 131, 110, CRYSTAL STRUCTURE OF DOC2B C2A DOMAIN
376, 2a5uA, 0.6938, 3.46, 0.153, 839, 118, CRYSTAL STRUCTURE OF HUMAN PI3KGAMMA COMPLEXED WITH AS605240
377, 2chwA, 0.6932, 3.36, 0.153, 840, 118, A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110 ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-39
378, 3nzuA, 0.6922, 3.14, 0.148, 822, 115, STRUCTURE-BASED OPTIMIZATION OF PYRAZOLO -PYRIMIDINE AND -PYRIDINE INHIBITORS OF PI3-KINASE
379, 2chzA, 0.6922, 3.39, 0.144, 839, 118, A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-93
380, 5g2nA, 0.6920, 3.24, 0.148, 823, 115, X-RAY STRUCTURE OF PI3KINASE GAMMA IN COMPLEX WITH COPANLISIB
381, 3l08A, 0.6914, 3.35, 0.157, 828, 115, STRUCTURE OF PI3K GAMMA WITH A POTENT INHIBITOR: GSK2126458
382, 2k4aA, 0.6910, 2.57, 0.266, 128, 109, FGF-1-C2A BINARY COMPLEX STRUCTURE: A KEY COMPONENT IN THE FIBROBLAST GROWTHFACTOR NON-CLASSICAL PATHWAY
383, 4aofA, 0.6909, 3.08, 0.148, 836, 115, SELECTIVE SMALL MOLECULE INHIBITOR DISCOVERED BY CHEMOPROTEOMIC ASSAY PLATFORM REVEALS REGULATION OF TH17 CELL DIFFERENTIATION BY PI3KGAMMA
384, 4icxA, 0.6907, 3.04, 0.164, 132, 116, N-TERMINAL C2 DOMAIN OF HUMAN CEP120
385, 2k3hA, 0.6907, 2.63, 0.227, 127, 110, STRUCTURAL DETERMINANTS FOR CA2+ AND PIP2 BINDING BY THE C2A DOMAIN OF RABPHILIN-3A
386, 6flkA, 0.6906, 2.68, 0.112, 154, 116, CRYSTAL STRUCTURE OF CEP120 C2C DOMAIN
387, 4icxC, 0.6902, 2.99, 0.148, 130, 115, N-TERMINAL C2 DOMAIN OF HUMAN CEP120
388, 6flkB, 0.6900, 2.72, 0.112, 154, 116, CRYSTAL STRUCTURE OF CEP120 C2C DOMAIN
389, 2cm5A, 0.6900, 2.13, 0.233, 141, 103, CRYSTAL STRUCTURE OF THE C2B DOMAIN OF RABPHILIN
390, 3sd5A, 0.6896, 3.03, 0.152, 817, 112, CRYSTAL STRUCTURE OF PI3K GAMMA WITH 5-(24-DIMORPHOLINOPYRIMIDIN-6- YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
391, 3p2bA, 0.6896, 3.01, 0.152, 808, 112, CRYSTAL STRUCTURE OF PI3K GAMMA WITH 3-(2-MORPHOLINO-6-(PYRIDIN-3- YLAMINO)PYRIMIDIN-4-YL)PHENOL
392, 5sw8A, 0.6893, 3.29, 0.144, 1030, 118, CRYSTAL STRUCTURE OF PI3KALPHA IN COMPLEX WITH FRAGMENTS 7 AND 11
393, 6ewiB, 0.6891, 3.22, 0.099, 182, 121, OREOCHROMIS NILOTICUS CEP120 SECOND C2 DOMAIN (C2B) A200P + G307S MUTANT 
394, 4kz0A, 0.6891, 3.12, 0.159, 833, 113, STRUCTURE OF PI3K GAMMA WITH IMIDAZOPYRIDINE INHIBITORS
395, 6ewiA, 0.6889, 3.23, 0.099, 174, 121, OREOCHROMIS NILOTICUS CEP120 SECOND C2 DOMAIN (C2B) A200P + G307S MUTANT 
396, 2ki6A, 0.6887, 2.56, 0.266, 128, 109, THE FGF1-S100A13-C2A HETERO-HEXAMERIC COMPLEX STRUCTURE: A COMPONENT IN THE NON-CLASSICAL PATHWAY FOR FGF1 SECRETION
397, 4kzcA, 0.6868, 3.03, 0.152, 821, 112, STRUCTURE OF PI3K GAMMA WITH IMIDAZOPYRIDINE INHIBITORS
398, 5i6uA, 0.6867, 3.07, 0.165, 816, 115, THE CRYSTAL STRUCTURE OF PI3KDELTA WITH COMPOUND 32
399, 2ki6F, 0.6856, 2.58, 0.266, 128, 109, THE FGF1-S100A13-C2A HETERO-HEXAMERIC COMPLEX STRUCTURE: A COMPONENT IN THE NON-CLASSICAL PATHWAY FOR FGF1 SECRETION
400, 1v27A, 0.6855, 2.99, 0.165, 141, 109, SOLUTION STRUCTURE OF THE FIRST C2 DOMAIN OF RIM2
401, 6gq7A, 0.6853, 3.17, 0.150, 802, 113, PI3KG IN COMPLEX WITH INH 
402, 3mjwA, 0.6849, 2.95, 0.153, 819, 111, PI3 KINASE GAMMA WITH A BENZOFURANONE INHIBITOR
403, 5w4sA, 0.6848, 3.11, 0.211, 139, 114, SOLUTION STRUCTURE OF C2 DOMAIN FROM PROTEIN KINASE C ALPHA IN TERNARY COMPLEX WITH CALCIUM AND V5-PHM PEPTIDE 
404, 3ml8A, 0.6836, 3.18, 0.149, 843, 114, DISCOVERY OF THE HIGHLY POTENT PI3K/MTOR DUAL INHIBITOR PF-04691502 THROUGH STRUCTURE BASED DRUG DESIGN
405, 4lcvA, 0.6821, 2.48, 0.231, 123, 104, CRYSTAL STRUCTURE OF DOC2B C2A DOMAIN
406, 3zw3A, 0.6814, 3.24, 0.150, 831, 113, FRAGMENT BASED DISCOVERY OF A NOVEL AND SELECTIVE PI3 KINASE INHIBITOR
407, 2nceA, 0.6812, 3.08, 0.214, 139, 112, SOLUTION STRUCTURE OF CA2+-BOUND C2 DOMAIN FROM PROTEIN KINASE C ALPHA IN THE FORM OF COMPLEX WITH V5-PHM PEPTIDE
408, 2k8mA, 0.6812, 2.49, 0.269, 128, 108, S100A13-C2A BINARY COMPLEX STRUCTURE
409, 3qjzA, 0.6811, 3.12, 0.153, 795, 111, CRYSTAL STRUCTURE OF PI3K-GAMMA IN COMPLEX WITH BENZOTHIAZOLE 1
410, 2k8mD, 0.6807, 2.50, 0.269, 128, 108, S100A13-C2A BINARY COMPLEX STRUCTURE
411, 2rd0A, 0.6806, 3.49, 0.158, 997, 120, STRUCTURE OF A HUMAN P110ALPHA/P85ALPHA COMPLEX
412, 2q3xA, 0.6806, 2.83, 0.159, 137, 107, THE RIM1ALPHA C2B DOMAIN
413, 4hvbA, 0.6795, 3.20, 0.150, 830, 113, CATALYTIC UNIT OF PI3KG IN COMPLEX WITH PI3K/MTOR DUAL INHIBITOR PF- 04979064
414, 2a4zA, 0.6786, 3.18, 0.150, 812, 113, CRYSTAL STRUCTURE OF HUMAN PI3KGAMMA COMPLEXED WITH AS604850
415, 2d8kA, 0.6785, 2.55, 0.287, 141, 108, SOLUTION STRUCTURE OF THE FIRST C2 DOMAIN OF SYNAPTOTAGMIN VII
416, 5jhaA, 0.6767, 3.05, 0.153, 803, 111, STRUCTURE OF PHOSPHOINOSITIDE 3-KINASE GAMMA (PI3K) BOUND TO THE POTENT INHIBITOR PIKIN2
417, 2k45A, 0.6763, 2.56, 0.269, 128, 108, C2A DOMAIN OF SYNAPTOTOTAGMIN I SOLUTION STRUCTURE IN THE FGF-1-C2A BINARY COMPLEX: KEY COMPONENT IN THE FIBROBLAST GROWTHFACTOR NON-CLASSICAL PATHWAY
418, 5t23A, 0.6742, 3.03, 0.153, 804, 111, PI3KG IN COMPLEX WITH 5D
419, 6fjcB, 0.6738, 2.42, 0.162, 129, 105, HUMAN KIBRA C2 DOMAIN MUTANT C771A IN COMPLEX WITH PHOSPHATIDYLINOSITOL 3;4;5-TRISPHOSPHATE 
420, 6fb4B, 0.6738, 2.47, 0.160, 129, 106, HUMAN KIBRA C2 DOMAIN MUTANT C771A 
421, 2dmgA, 0.6728, 2.91, 0.202, 142, 109, SOLUTION STRUCTURE OF THE THIRD C2 DOMAIN OF KIAA1228 PROTEIN
422, 2q3xB, 0.6724, 2.63, 0.163, 140, 104, THE RIM1ALPHA C2B DOMAIN
423, 2bwqA, 0.6716, 2.52, 0.186, 122, 102, CRYSTAL STRUCTURE OF THE RIM2 C2A-DOMAIN AT 1.4 ANGSTROM RESOLUTION
424, 6fjcA, 0.6696, 2.44, 0.162, 130, 105, HUMAN KIBRA C2 DOMAIN MUTANT C771A IN COMPLEX WITH PHOSPHATIDYLINOSITOL 3;4;5-TRISPHOSPHATE 
425, 6fb4A, 0.6695, 2.51, 0.160, 129, 106, HUMAN KIBRA C2 DOMAIN MUTANT C771A 
426, 6fjdA, 0.6694, 2.51, 0.160, 129, 106, HUMAN KIBRA C2 DOMAIN MUTANT C771A IN COMPLEX WITH PHOSPHATIDYLINOSITOL 4;5-BISPHOSPHATE 
427, 6fd0A, 0.6675, 2.62, 0.159, 129, 107, HUMAN KIBRA C2 DOMAIN MUTANT M734I S735A 
428, 5o83A, 0.6653, 3.11, 0.171, 794, 111, DISCOVERY OF CDZ173 (LENIOLISIB) REPRESENTING A STRUCTURALLY NOVEL CLASS OF PI3K DELTA-SELECTIVE INHIBITORS
429, 1ugkA, 0.6652, 2.55, 0.202, 138, 109, SOLUTION STRUCTURE OF THE FIRST C2 DOMAIN OF SYNAPTOTAGMIN IV FROM HUMAN FETAL BRAIN (KIAA1342)
430, 2yrbA, 0.6642, 3.26, 0.085, 156, 118, SOLUTION STRUCTURE OF THE FIRST C2 DOMAIN FROM HUMAN KIAA1005 PROTEIN
431, 5jhbA, 0.6633, 3.06, 0.156, 811, 109, STRUCTURE OF PHOSPHOINOSITIDE 3-KINASE GAMMA (PI3K) BOUND TO THE POTENT INHIBITOR PIKIN3
432, 1rh8A, 0.6598, 2.76, 0.222, 142, 108, THREE-DIMENSIONAL STRUCTURE OF THE CALCIUM-FREE PICCOLO C2A- DOMAIN
433, 6fd0B, 0.6570, 2.43, 0.163, 128, 104, HUMAN KIBRA C2 DOMAIN MUTANT M734I S735A 
434, 6fjdB, 0.6565, 2.47, 0.157, 126, 102, HUMAN KIBRA C2 DOMAIN MUTANT C771A IN COMPLEX WITH PHOSPHATIDYLINOSITOL 4;5-BISPHOSPHATE 
435, 2z0uA, 0.6557, 2.89, 0.159, 127, 107, CRYSTAL STRUCTURE OF C2 DOMAIN OF KIBRA PROTEIN
436, 2z0uB, 0.6543, 2.69, 0.162, 127, 105, CRYSTAL STRUCTURE OF C2 DOMAIN OF KIBRA PROTEIN
437, 2enpA, 0.6489, 2.91, 0.220, 147, 109, SOLUTION STRUCTURE OF THE FIRST C2 DOMAIN FROM HUMAN B/K PROTEIN
438, 1w16A, 0.6448, 2.35, 0.219, 125, 96, RAT SYNAPTOTAGMIN 4 C2B DOMAIN IN THE ABSENCE OF CALCIUM
439, 2lhaA, 0.6399, 3.09, 0.257, 151, 109, SOLUTION STRUCTURE OF C2B WITH IP6
440, 4mjjA, 0.6374, 2.39, 0.250, 116, 96, CRYSTAL STRUCTURE OF THE C2A DOMAIN OF DOC2A
441, 2y3aA, 0.6329, 3.62, 0.094, 976, 117, CRYSTAL STRUCTURE OF P110BETA IN COMPLEX WITH ICSH2 OF P85BETA AND THE DRUG GDC-0941
442, 4bfrA, 0.6274, 3.09, 0.163, 855, 104, DISCOVERY AND OPTIMIZATION OF PYRIMIDONE INDOLINE AMIDE PI3KBETA INHIBITORS FOR THE TREATMENT OF PHOSPHATASE AND TENSIN HOMOLOGUE (PTEN)-DEFICIENT CANCERS
443, 5is5A, 0.6135, 3.34, 0.162, 785, 105, DISCOVERY AND PHARMACOLOGICAL CHARACTERIZATION OF NOVEL QUINAZOLINE- BASED PI3K DELTA-SELECTIVE INHIBITORS
